CN103813797B - 一种用于治疗自身免疫性疾病的组合物和方法 - Google Patents
一种用于治疗自身免疫性疾病的组合物和方法 Download PDFInfo
- Publication number
- CN103813797B CN103813797B CN201280045735.5A CN201280045735A CN103813797B CN 103813797 B CN103813797 B CN 103813797B CN 201280045735 A CN201280045735 A CN 201280045735A CN 103813797 B CN103813797 B CN 103813797B
- Authority
- CN
- China
- Prior art keywords
- mice
- eae
- composition
- disease
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161536824P | 2011-09-20 | 2011-09-20 | |
| US61/536,824 | 2011-09-20 | ||
| US201161537229P | 2011-09-21 | 2011-09-21 | |
| US61/537,229 | 2011-09-21 | ||
| PCT/IB2012/002252 WO2013041963A2 (en) | 2011-09-20 | 2012-09-19 | A composition and method for treating an autoimmune disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103813797A CN103813797A (zh) | 2014-05-21 |
| CN103813797B true CN103813797B (zh) | 2017-07-11 |
Family
ID=47914967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280045735.5A Active CN103813797B (zh) | 2011-09-20 | 2012-09-19 | 一种用于治疗自身免疫性疾病的组合物和方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9901638B2 (enExample) |
| EP (1) | EP2758061B1 (enExample) |
| JP (1) | JP6035340B2 (enExample) |
| KR (1) | KR101987512B1 (enExample) |
| CN (1) | CN103813797B (enExample) |
| AU (1) | AU2012311235B2 (enExample) |
| BR (1) | BR112014006473A2 (enExample) |
| CA (1) | CA2849255C (enExample) |
| CL (1) | CL2014000671A1 (enExample) |
| DK (1) | DK2758061T3 (enExample) |
| ES (1) | ES2614923T3 (enExample) |
| HU (1) | HUE032959T2 (enExample) |
| IL (1) | IL231489A (enExample) |
| IN (1) | IN2014CN02908A (enExample) |
| MX (1) | MX347660B (enExample) |
| PL (1) | PL2758061T3 (enExample) |
| PT (1) | PT2758061T (enExample) |
| RU (1) | RU2621129C2 (enExample) |
| SG (1) | SG11201400386RA (enExample) |
| TW (1) | TWI573590B (enExample) |
| WO (1) | WO2013041963A2 (enExample) |
| ZA (1) | ZA201401954B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2910983C (en) * | 2013-04-30 | 2021-11-02 | Thomas Julius Borody | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
| EP3145510B8 (en) * | 2014-05-22 | 2021-10-27 | Kuenstner, John, Todd | Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics |
| MX2017005350A (es) * | 2014-10-24 | 2017-08-15 | Redhill Biopharma Ltd | Terapia para la inhibicion de la replicacion del virus de arn monocatenario. |
| BR112018003232A2 (pt) * | 2015-10-06 | 2018-09-25 | Redhill Biopharma Ltd | terapias de combinação para tratamento de câncer |
| CN109219615B (zh) | 2016-05-02 | 2022-12-09 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| AR113011A1 (es) | 2017-09-08 | 2020-01-15 | Evelo Biosciences Inc | Vesículas extracelulares bacterianas |
| CA3187031A1 (en) * | 2020-06-30 | 2022-01-06 | Redhill Biopharma Ltd. | Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections |
| WO2023182288A1 (ja) * | 2022-03-22 | 2023-09-28 | 国立大学法人京都大学 | シャルコー・マリー・ツース病の治療または予防薬 |
| CN116649295A (zh) * | 2023-03-20 | 2023-08-29 | 广西医科大学第一附属医院 | GluN1359-378多肽主动免疫PTZ诱发癫痫及认知障碍的动物模型、建立方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69839261T2 (de) * | 1997-04-01 | 2009-03-26 | Borody, Thomas Julius, Five Dock | Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen |
| US7488580B1 (en) | 2005-03-10 | 2009-02-10 | University Of Central Florida Research Foundation, Inc. | Protocol for detection of Mycobacterium avium subspecies paratuberculosis in blood |
| US20090054380A1 (en) * | 2005-12-20 | 2009-02-26 | Greenstein Robert J | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection |
| US20080275063A1 (en) | 2007-04-24 | 2008-11-06 | Heike Schauerte | Inhibitors of protein kinases |
| EP2200613B1 (en) * | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
| NZ587250A (en) * | 2008-02-08 | 2011-12-22 | Red Hill Biopharma Ltd | Methods and compositions for treating inflammatory bowel disease |
| US20120237472A1 (en) * | 2009-07-24 | 2012-09-20 | The Johns Hopkins University | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
-
2012
- 2012-09-18 TW TW101134166A patent/TWI573590B/zh not_active IP Right Cessation
- 2012-09-19 CA CA2849255A patent/CA2849255C/en active Active
- 2012-09-19 DK DK12834382.9T patent/DK2758061T3/en active
- 2012-09-19 IN IN2908CHN2014 patent/IN2014CN02908A/en unknown
- 2012-09-19 EP EP12834382.9A patent/EP2758061B1/en active Active
- 2012-09-19 CN CN201280045735.5A patent/CN103813797B/zh active Active
- 2012-09-19 US US14/345,839 patent/US9901638B2/en active Active
- 2012-09-19 WO PCT/IB2012/002252 patent/WO2013041963A2/en not_active Ceased
- 2012-09-19 HU HUE12834382A patent/HUE032959T2/hu unknown
- 2012-09-19 MX MX2014003430A patent/MX347660B/es active IP Right Grant
- 2012-09-19 RU RU2014115807A patent/RU2621129C2/ru active
- 2012-09-19 KR KR1020147010372A patent/KR101987512B1/ko not_active Expired - Fee Related
- 2012-09-19 SG SG11201400386RA patent/SG11201400386RA/en unknown
- 2012-09-19 AU AU2012311235A patent/AU2012311235B2/en not_active Ceased
- 2012-09-19 ES ES12834382.9T patent/ES2614923T3/es active Active
- 2012-09-19 PT PT128343829T patent/PT2758061T/pt unknown
- 2012-09-19 JP JP2014531331A patent/JP6035340B2/ja active Active
- 2012-09-19 BR BR112014006473A patent/BR112014006473A2/pt not_active Application Discontinuation
- 2012-09-19 PL PL12834382T patent/PL2758061T3/pl unknown
-
2014
- 2014-03-12 IL IL231489A patent/IL231489A/en active IP Right Grant
- 2014-03-17 ZA ZA2014/01954A patent/ZA201401954B/en unknown
- 2014-03-19 CL CL2014000671A patent/CL2014000671A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103813797B (zh) | 一种用于治疗自身免疫性疾病的组合物和方法 | |
| CN107669668A (zh) | 治疗多发性硬化症的组合疗法 | |
| JP2012126736A (ja) | 炎症性腸疾患を治療するための方法および組成物 | |
| EP4275750A2 (en) | Treatment of alzheimer's disease in a particular patient population | |
| EP2911510B1 (en) | Medicinal treatment of dermal diseases in companion animals with norketotifen | |
| KR20250083233A (ko) | 화농성 한선염 치료를 위한 방법 및 조성물 | |
| CN104379142B (zh) | 用于免疫调节的拉多替吉治疗 | |
| JP2019531352A (ja) | ベルベリンナノ粒子を用いた免疫疾患の治療 | |
| WO2014070696A2 (en) | Medicinal treatment of chronic dermal inflammatory diseases with norketotifen | |
| EP3621628B1 (en) | Method for treating multiple sclerosis using arsenic trioxide | |
| US20250195552A1 (en) | Methods of using avermectin compositions for the treatment of inflammatory disorders and dosing regimens | |
| CN112402420A (zh) | 钩吻素子在制备用于治疗炎症性肠病的药物中的用途 | |
| US20250108078A1 (en) | Mechanistic bacterial efector to prevent apoptosis of human beta cells | |
| US8802691B2 (en) | Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response | |
| HK40094581A (en) | Treatment of alzheimer's disease in a particular patient population | |
| WO2023180955A1 (en) | Methods of using avermectin compositions for the treatment of neurological disorders and dosing regimens | |
| CN118340898A (zh) | 用于治疗溃疡性结肠炎的药物 | |
| EP3509602A1 (en) | Uses of triterpenoid mixture for treating multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |